The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) have reaffirmed the Human Epidermal Growth Factor Receptor 2 (HER2) Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results.
The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that a treatment traditionally used for “HER2 positive” patients was also effective in patients considered “HER2 negative.” As a result of this trial, pathologists were uncertain if new reporting categories, such as a “HER2 Low” category, were needed to identify patients eligible for this treatment.
After reviewing results of the DESTINY-Breast04 trial and other studies, the CAP/ASCO panel determined that the current HER2 testing recommendations remain valid to identify all breast cancer patients who might benefit from the full spectrum of HER2 related therapies. While no changes to reporting terminology are recommended, the guideline update emphasizes awareness of the new clinical significance of the specific HER2 protein levels reported. In addition, a new reporting comment footnote is recommended to clarify the new clinical relevance of the specific HER2 protein expression levels.
The recent results of the Breast-DESTINY04 trial using the antibody drug conjugate trastuzumab deruxtecan expanded the drug’s approval beyond traditional ‘HER2 positive’ breast cancers in metastatic patients.
The CAP/ASCO HER2 Breast Cancer Testing Guideline update was published as an early online release in the Archives of Pathology & Laboratory Medicine and the Journal of Clinical Oncology on June 7.
